Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 4 Number 1
Volume 4 Number 2
Volume 4 Number 3
Volume 4 Number 4
Volume 4 Number 5
Volume 4 Number 6
Volume 4 Number 7
Volume 4 Number 8
Volume 4 Number 9
Volume 4 Number 10
Volume 4 Number 11
Volume 5 Number 1
Volume 5 Number 2
Volume 5 Number 3
Volume 5 Number 4
Volume 5 Number 5
Volume 5 Number 6
Volume 5 Number 7
Volume 5 Number 8
Volume 5 Number 9
Volume 5 Number 10
Volume 5 Number 11
Volume 6 Number 1
Volume 6 Number 2
Volume 6 Number 3
Volume 6 Number 4
Volume 6 Number 5
Volume 6 Number 6
Regular updates from the global world of pharmacy.
Access and click on the title links that are illustrated.
In the April edition of i2P, a story involving the ministerial removal of pharmacy location rules was published.
It involved a disparate group of Colac residents coming together to fight the location rules and to establish a third independent pharmacy.
The story was important for a number of important reasons:
(i) The Colac residents did not want a "chain-type" pharmacy.
(ii) They wanted true competition between local pharmacies to avoid a perceived monopoly.
(iii) They wanted good old-fashioned pharmacy personalised service in an appropriate time frame.
As pharmacists we often bemoan the spectre of "Colesworth" providing pharmacy services and the potential for them to strip personalised service out of the independent pharmacy environment.
Yet the existing Colac pharmacies (having the same owner) did exactly that.
The question I pose is if this is the direction of pharmacy (as formulated by the PGA supply side pharmacy and warehouse-type pharmacies) the Colac community have clearly demonstrated that those models are not the preferred version.
i2P asked Jeanette Sell to tell her story in her own words.
Health Reform? Is that what we have been given by COAG: I don’t think so at all. It is wrong from the get go. In that 60% will come from here; 30% will be taken away from there; 40% will be paid by them and we will layer some more highly experienced and very necessary bureaucrats on the top to make sure no one ever knows what is actually going on.
Same old, same old, just tarted up differently so the punters think something is happening.
Health Reform it aren’t. Pretending to reform hospital funding it is.
Not a word about technology, e-health, savings, over-staffing of suits in place of white coats and blue blouses, blame shifting, waste, incompetence and all the other ills that riddle the hospital operational (non-clinical related) networks.
And there are enough ills for a zillion hypochondriacs to wallow in. Just this past week I had occasion to sample it first hand with a relative that needed emergency attention. The ambulance picked her up at 6:55 pm, after just a ten minute wait. We arrived at the hospital about the same time as the ambulance at 7:15 pm.
So far so good.
On July 1 2006, the Federal Government reduced the pharmacy wholesaling margin from 10% to 7%. This action was an outcome of the Government’s negotiations with the Pharmacy Guild as these two parties hammered out the 5 year deal that was the Fourth Community Pharmacy Agreement (4CPA).
To put this change into today’s context, Sigma’s wholesaling business turned over around $2.4 billion in the last twelve months.
If 70% of this turnover is generated by dispensary medicines, and if 65% of these are PBS items, then the 4CPA pulled about $33 million in revenues off Sigma’s top line in today’s dollars.
Living in outback Queensland, especially during the long periods of drought, the elderly grazier has struggled from day-to-day to keep his cattle property going.
He had only been 12 years old when his father died, but with the Second World War still raging, and with no men available, the local police officer had issued him with a drivers licence and told him to go home to help his mother run the property.
That had been the end of his schooling and to this day, he can still barely read and write.
Tasmanian pharmacists now have access to the Pharmacists’ Support Service (PSS), developed by the Victorian PSA.
It can be contacted by phone on the toll free number: 1300 244 910.
Consumers and the Australian Government are paying up to 10 times more for generic cholesterol-lowering drugs compared to the United Kingdom, according to research carried out by health economists at the University of Sydney.
A recent study published by the Medical Journal of Australia (MJA) found Australia could have saved approximately $900 million on statin treatments (drugs used to lower cholesterol) over the past four years and could save up to an additional $3.2 billion over the next 10 years.
Pharmacy designers in Australia have yet to come up with a zero emission pharmacy building, but they will have a model t draw from in the form of an AusZEH private home, designed and built by CSIRO.
Designed to fit the Australian climate – and the lifestyle of a typical middle-income family – Australia's first Zero Emission House (AusZEH) has been officially opened in Melbourne.
Working with industry partners Delfin-Lend Lease and the Henley Property Group, and supported by the AusZEH consortium, CSIRO designed and built the demonstration house 30 kilometres north of Melbourne’s CBD, in the community of Laurimar in Doreen, Victoria.
The eight-star energy-efficiency rated AusZEH showcases off-the-shelf building and renewable energy-generation technologies, and new future-ready energy management systems.
Nearly 13 per cent of Australia’s greenhouse gas emissions are due to home energy use.
With the changes occurring restricting the sale of analgesic products within pharmacies, there has not been a great deal of discussion as to how best to handle these changes.
It has been said that the new processes impact severely on the pharmacist’s workflow.
The analgesic market is a very large one within pharmacy and the ability to lose a major income stream is very real.
The following is a press release from the PSA and we have asked Mark Coleman to comment on the various issues: